Clinical Trial Update: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term safety and efficacy of rFVIIIFc for prevention and treatment of bleeding in previously treated participants with Hemophilia A;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFVIIIFc (recombinant factor VIII Fc fusion protein)

Snippet

Sponsor: Bioverativ Therapeutics Inc. | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-11-23